

Product Monograph
Including Patient Medication Information

Pr **PENTASA**®

Mesalazine*

Tablet (Extended-Release), For oral use, 500 mg and 1 g-of mesalazine

Suspension, For rectal use (enema), 1 g and 4 g/100 mL of mesalazine

Suppository, For rectal use, 1 g of mesalazine

(*also called 5-aminosalicylic acid, 5-ASA or mesalamine)

Lower Gastrointestinal anti-inflammatory

Ferring Inc.
200 Yorkland Blvd, Suite 500
North York, Ontario
M2J 5C1

Date of Authorization:
2026-04-16

Control Number: 304193
® Registered Trademark of Ferring BV

Recent Major Label Changes

7 Warnings and Precautions	2024-06
7 Warnings and Precautions, Renal	2026-04

Table of Contents

Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.

Recent Major Label Changes	2
Table of Contents	2
Part 1: Healthcare Professional Information	5
1. Indications	5
1.1. Pediatrics.....	5
1.2. Geriatrics	5
2. Contraindications	5
4. Dosage and Administration	6
4.2. Recommended Dose and Dosage Adjustment	6
4.4. Administration	6
4.5. Missed Dose	6
5. Overdose	6
6. Dosage Forms, Strengths, Composition and Packaging	7
7. Warnings and Precautions	8
General	8
Cardiovascular	8
Gastrointestinal	8
Hematologic	9
Hepatic/Biliary/Pancreatic	9
Renal	9
Reproductive Health.....	9
Fertility	9
Respiratory	10

Skin	10
7.1. Special Populations	10
7.1.1. Pregnancy.....	10
7.1.2. Breastfeeding.....	10
7.1.3. Pediatrics.....	10
7.1.4. Geriatrics.....	10
8. Adverse Reactions	11
8.1. Adverse Reaction Overview	11
8.2. Clinical Trial Adverse Reactions	11
8.3. Less Common Clinical Trial Adverse Reactions.....	15
8.5. Post-Market Adverse Reactions.....	17
9. Drug Interactions.....	17
9.2. Drug Interactions Overview	17
9.3. Drug-Behaviour Interactions.....	17
9.4. Drug-Drug Interactions	17
9.5. Drug-Food Interactions	18
9.6. Drug-Herb Interactions	18
9.7. Drug-Laboratory Test Interactions.....	18
10. Clinical Pharmacology.....	18
10.1. Mechanism of Action.....	18
10.2. Pharmacodynamics.....	19
10.3. Pharmacokinetics	19
11. Storage, Stability, and Disposal.....	22
Part 2: Scientific Information	23
13. Pharmaceutical Information	23
14. Clinical Trials	24
14.1. Clinical Trials by Indication	24
Active Ulcerative Colitis and Ulcerative Colitis in Remission.....	24
Crohn’s Disease.....	26
Active Proctitis and Distal Ulcerative Colitis.....	27
14.2. Comparative Bioavailability Studies	29
15. Microbiology	30

16. Non-Clinical Toxicology.....	30
Patient Medication Information	31
Patient Medication Information	38
Patient Medication Information	47

Part 1: Healthcare Professional Information

1. Indications

PENTASA (mesalazine) extended-release tablets are indicated for:

- Treatment of mild to moderate active ulcerative colitis and for long-term maintenance therapy in order to maintain remission and prevent relapse of active disease.
- Management of mild to moderate Crohn's Disease and maintenance of Crohn's Disease in remission induced by surgery or medication

PENTASA (mesalazine) rectal suspension is indicated for:

- Treatment of acute distal ulcerative colitis extending to the splenic flexure and for long-term maintenance therapy in order to maintain remission and prevent relapse of active disease. Clinical experience has shown that topical PENTASA (i.e. enemas/suppositories) is superior to oral PENTASA (i.e. tablets) with regard to therapeutic efficacy in distal ulcerative colitis (Table 3 - Clinical experience from pivotal trials).

PENTASA (mesalazine) suppositories are indicated for:

- Treatment of acute ulcerative proctitis and for long-term maintenance therapy in order to maintain remission and prevent relapse of active disease.

1.1. Pediatrics

Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

1.2. Geriatrics

Geriatrics (≥65 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use.

2. Contraindications

PENTASA is contraindicated in:

- Patients with existing gastric or duodenal ulcer;
- Patients with urinary tract obstruction, renal parenchymal disease or severe renal impairment. Very rarely, mesalazine may induce nephrotoxicity which would be additive in these patients. Renal function should be determined prior to beginning therapy (e.g. serum creatinine), and the benefits of therapy versus the increased risk of nephrotoxicity carefully assessed. See [7 Warnings and Precautions](#).
- PENTASA is contraindicated in patients who are hypersensitive to any salicylates (including mesalamine/mesalazine) or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 Dosage Forms, Strengths, Composition and Packaging](#).
- Patients with severe hepatic impairment. See [7 Warnings and Precautions](#).
- Infants under 2 years of age.

4. Dosage and Administration

4.2. Recommended Dose and Dosage Adjustment

- **Extended-release tablets (500 mg and 1g):** Management of mild to moderate active ulcerative colitis and maintenance therapy: Therapy should be initiated at 0.5 g four times daily (2 g daily dose). The dose may be increased to 1 g four times daily (4 g daily dose) if additional therapeutic benefit is needed.

Management of mild to moderate Crohn's disease: The optimal dose is 1 g four times daily (4 g daily dose). For patients with Crohn's Disease in remission, a dose of 3 g daily in divided doses is recommended.

- **Rectal suspension:** The recommended dose ranges from 1 g to 4 g of mesalazine, depending on disease activity. PENTASA may be self-administered once daily at bedtime. Dosage may be adjusted according to the individual patient's needs consistent with therapeutic goals. Prolonged retention is expected to achieve the best therapeutic response.
- **Suppositories:** The usual dose of PENTASA suppositories is one suppository containing 1 g of mesalazine, self-administered once daily at bedtime. Prolonged retention is expected to achieve the best therapeutic response. The frequency of dosage may be adjusted according to the individual patient's needs consistent with therapeutic goals.

4.4. Administration

- PENTASA extended-release tablets should not be chewed, broken or crushed but should be swallowed whole.
- PENTASA extended-release tablets should be taken with meals.

4.5. Missed Dose

- **Extended-release tablets (500 mg and 1g):** If you forget to take your tablets, then take them as usual the next day. Do not take a double dose to make up for a forgotten tablet.
- **Rectal suspension:** If you forget to take your dose before bedtime, take the medication as soon as you remember IF you will be able to retain the enema. If this is not possible administer the next bedtime dose, the next evening.
- **Suppositories:** If you forget to take your dose before bedtime, take the medication as soon as you remember IF you will be able to retain the suppository. If this is not possible administer the next bedtime dose, the next evening.

5. Overdose

There is no clinical experience with PENTASA overdosage. Single oral doses of mesalazine up to 5 g/kg in pigs and a single intravenous dose of mesalazine at 920 mg/kg in rats were not lethal.

Since PENTASA is an amino salicylate, symptoms of salicylate toxicity such as acid-base balance disorder, hyperventilation, pulmonary edema, vomiting, dehydration and hypoglycaemia may occur.

There is no specific antidote and the management of overdose is supportive and symptomatic. In cases of suspected overdose, symptomatic treatment at hospital is required. Fluid and electrolyte, as well as acid/base imbalances, should be corrected by the administration of appropriate intravenous therapy.

Close monitoring of renal function is required in order to maintain adequate renal function. No cases of overdose have been reported.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669).

6. Dosage Forms, Strengths, Composition and Packaging

Table 1 – Dosage Forms, Strengths, and Composition

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Oral	Tablet/ 500 mg, 1 g	Ethylcellulose, magnesium stearate, Microcrystalline cellulose, povidone and talc.
Rectal	Suspension(enema)/ 1 g and 4 g/100 mL	Purified water, sodium acetate, sodium edetate, sodium metabisulfite, with hydrochloric acid to adjust the pH to 4.8.
Rectal	Suppository/ 1 g	Magnesium stearate, polyethylene glycol, povidone, talc

Note: All Pentasa products are Phthalate Free.

Description

Extended-release Tablets:

- PENTASA tablets do not contain gluten, phthalates, or lactose.
- PENTASA 500 mg Extended Release Tablets are round, white-grey to pale brown speckled tablets with a scoreline on one side and embossed "500 mg" on one side and "PENTASA" on the other. They are available in unit dose blister strips of 10 tablets, in packages of 10 strips.
- PENTASA 1g Extended Release Tablets are oblong, white-grey to pale brown speckled tablets embossed PENTASA on both sides. They are available in unit dose blister strips of 10 tablets, in packages of 6 strips.

Rectal Suspension:

- Each carton contains 7 enemas together with 7 hygienic bags.
- PENTASA rectal suspension is supplied in a low density polyethylene (LDPE) bottle.

Suppositories:

- Suppositories are packaged in blister cards of 7 suppositories per card. Each carton contains 4 cards of 7 suppositories for a total of 28 suppositories.
- PENTASA suppositories are sealed in aluminium blisters made of double aluminium push through foils.

7. Warnings and Precautions

General

Some patients who have experienced a hypersensitivity reaction to sulfasalazine may have a similar reaction to PENTASA or other compounds that contain or are converted to mesalazine. Therefore, caution should be exercised when treating patients allergic to sulfasalazine due to the potential risk of cross sensitivity reactions between sulfasalazine and mesalazine.

Hypersensitivity reactions include:

- Severe cutaneous adverse reactions (SCARs), including Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) (see [7 Warnings and Precautions – Skin](#)).
- Mesalazine has been associated with an acute intolerance syndrome that may be difficult to distinguish from a flare of inflammatory bowel disease. Although the exact frequency of occurrence has not been determined, it has occurred in 3% of patients in controlled clinical trials of mesalazine or sulfasalazine. Symptoms include abdominal cramping, acute abdominal pain and bloody diarrhea, sometimes fever, severe headache and rash. If acute intolerance syndrome is suspected, prompt withdrawal is required.

In patients with mild to moderate renal impairment, mesalazine products should be used only if the benefits outweigh the risks. Therefore, caution should be exercised, and it is recommended that all patients have an evaluation of renal function prior to initiation of therapy, and periodically while on treatment. (see [7 Warnings and Precautions – Renal](#)).

In patients with mild to moderate impaired liver function, mesalazine products should be used only if the expected benefits outweigh the risks to the patient. Caution should be exercised. (see [7 Warnings and Precautions – Hepatic/Biliary/Pancreatic](#)).

PENTASA extended-release tablets should not be chewed, broken or crushed but should be swallowed whole.

Cardiovascular

Mesalazine induced cardiac hypersensitivity reactions (myocarditis and pericarditis) have been reported rarely with mesalazine and other mesalazine-containing preparations. Caution should be taken in prescribing this medication to patients with conditions predisposing to the development of myocarditis or pericarditis.

Gastrointestinal

Organic or functional obstruction in the upper gastrointestinal tract may delay onset of action of the product.

Mesalazine has also been associated with an acute intolerance syndrome, which may be difficult to distinguish from a flare of inflammatory bowel disease (see [7 Warnings and Precautions](#)).

Hematologic

Following mesalazine treatment, serious blood dyscrasias (including myelosuppression) have been reported rarely. The risk is further increased when mesalazine products are used concomitantly with 6-mercaptopurine or azathioprine (see [9.4 Drug-Drug Interactions](#)). Blood test for differential blood count is recommended prior to and during treatment, at the discretion of the treating physician. If the patient develops unexplained bleeding, bruising, purpura, anaemia, fever or sore throat, haematological investigations should be performed. If there is suspicion of blood dyscrasia, mesalazine treatment should be discontinued.

Hepatic/Biliary/Pancreatic

There have been reports of hepatic failure and increased liver enzymes in patients with pre-existing liver disease when treated with mesalazine products. Therefore, mesalazine is contraindicated in patients with severe hepatic impairment (see [2 Contraindications](#)). In patients with mild to moderate liver function impairment, caution should be exercised and mesalazine products should only be used if the expected benefit clearly outweighs the risks to the patients. Appropriate assessment and monitoring of liver function parameters like ALT or AST should be performed prior to and during treatment, at the discretion of the treating physician.

Renal

Reports of renal impairment, including minimal change nephropathy, and acute or chronic interstitial nephritis have been associated with mesalazine products and pro-drugs of mesalazine. Cases of nephrolithiasis have been reported with the use of mesalazine including stones with a 100% mesalazine content. It is recommended to ensure adequate fluid intake during treatment. Mesalazine is contraindicated in patients with severe renal impairment (see [2 Contraindications](#)). In patients with mild to moderate renal dysfunction, caution should be exercised and mesalazine products should be used only if the benefits outweigh the risks. It is recommended that all patients have an evaluation of renal function (e.g. serum creatinine), prior to initiation of therapy and periodically while on treatment, especially during the initial phase of treatment. Mesalazine induced nephrotoxicity should be suspected in patients developing renal dysfunction during treatment. Mesalazine treatment should be discontinued immediately if renal function deteriorates. The concurrent use of other known nephrotoxic agents may increase the risk of renal reactions, thus requiring increased monitoring frequency of renal function.

Reproductive Health

Fertility

Semen abnormalities and infertility in men, which are associated with sulfasalazine, have not been reported with PENTASA during controlled clinical trials. Semen quality significantly may improve when patients are transferred from sulfasalazine to PENTASA.

Decreased sperm count and impaired sperm motility have been only rarely reported with mesalazine. This effect may be reversible when treatment is discontinued.

Respiratory

Patients with chronic lung function impairment, especially asthma, are at risk of hypersensitivity reactions with mesalazine products and should be closely monitored.

Skin

SCARs, including DRESS, SJS and TEN have been reported in association with mesalazine treatment. Mesalazine should be discontinued, at the first appearance of signs and symptoms of severe skin reactions, such as skin rash, mucosal lesions, or any other sign of hypersensitivity.

7.1. Special Populations

7.1.1. Pregnancy

There are no adequate and well controlled studies of mesalazine in pregnant women. Mesalazine is known to cross the placental barrier.

PENTASA should be used during pregnancy only if benefits outweigh the risks. The underlying condition itself (Inflammatory bowel disease/IBD) may increase risks for the pregnancy outcome.

Limited published human data on mesalazine show no increase in the overall rate of congenital malformations. Limited published data on the class of mesalamine products show an increased rate of preterm birth, stillbirth, and low birth weight. These adverse pregnancy outcomes are also associated with active inflammatory bowel disease.

Blood disorders (pancytopenia, leucopenia, thrombocytopenia, anemia) have been reported in newborns of mothers being treated with PENTASA.

7.1.2. Breastfeeding

In nursing mothers, mesalazine is excreted in breast milk at concentration much lower than in maternal blood, but the metabolite N-acetyl-5-ASA appears in similar concentrations. Caution should be exercised, and PENTASA should be used in nursing mothers only if the benefits outweigh the risks. Hypersensitivity reactions like diarrhea in the infants cannot be excluded. No controlled studies with PENTASA during breast feeding have been carried out.

When Pentasa is used in nursing women, infants should be monitored for changes in stool consistency. If the infant develops diarrhea, breastfeeding should be discontinued. Cases of diarrhea in breastfed infants exposed to mesalazine have been reported.

7.1.3. Pediatrics

Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

7.1.4. Geriatrics

Geriatrics (≥65 years of age): There are no clinical efficacy studies of mesalazine in geriatrics patients.

Results of a single-dose pharmacokinetic study indicate that following the administration of a mesalamine-containing product, the systemic exposure to mesalamine may be increased by up to 2-fold in elderly subjects (> 65 years), as compared with younger adult subjects (18-35 years). Systemic exposures were inversely correlated with renal function. Therefore, dose selection for elderly patients should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concurrent disease or other drug therapy.

8. Adverse Reactions

8.1. Adverse Reaction Overview

The most frequent adverse reactions seen in clinical trials are diarrhoea, nausea, abdominal pain, headache, vomiting, and rash. Hypersensitivity reactions and drug fever may occasionally occur, and severe cutaneous adverse reactions, including Drug reaction with eosinophilia and systemic symptoms (DRESS) Stevens-Johnson Syndrome (SJS) and Toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment.

8.2. Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. Therefore, the frequencies of adverse reactions observed in the clinical trials may not reflect frequencies observed in clinical practice and should not be compared to frequencies reported in clinical trials of another drug.

The following adverse events (AEs) were reported in the CAMMP clinical study (Table 2) using the PENTASA extended release tablets in adult patients with mild to moderate ulcerative colitis. A total of 143 patients received PENTASA Extended-release tablets of which 93 patients received PENTASA 4g /day for 8-week (induction phase) and 70 went on to a 24-week maintenance phase at 2 g/day.

Table 2 - Adverse events, occurring in $\geq 2\%$ of patients treated with PENTASA Extended-release tablets formulation (CAMMP Study 2011)

System organ class/preferred term	Mesalazine n =143 (%)	Placebo n = 144 (%)
Patients with any adverse event	52.4%	45.1%
Nasopharyngitis	8.4%	4.2%
Headache	7.7%	9.0%
Nausea	4.2%	4.2%
Influenza	3.5%	3.5%
Gastroenteritis	3.5%	3.5%
Colitis ulcerative	2.8%	6.3%
Abdominal pain	2.8%	2.8%
Fatigue	2.8%	2.8%
Cough	2.8%	2.8%
Pyrexia	2.1%	2.1%
Flatulence	2.1%	2.1%
Back pain	2.1%	2.1%
Dizziness	2.1%	2.1%
Pharyngolaryngeal pain	2.1%	2.1%

In this clinical trial, other AEs occurring in less than 2% of patients included rash & pruritus, dyspepsia, vomiting, diarrhoea, haemorrhoids, rectal haemorrhage, hepatic enzyme increased, myalgia/arthralgia, pain in extremity, otitis media, and pneumonia.

Table 3 - Frequency of adverse effects, based on other clinical trials reports with other PENTASA formulations, and from post-marketing surveillance data with all PENTASA formulations

Frequency of adverse effect	Organ system affected	Symptom
Common (> 1% and < 10%)	<p>General disorders and administration site conditions</p> <p>Nervous system disorders</p> <p>Cardiovascular System</p> <p>Gastro-intestinal disorders</p> <p>Skin and subcutaneous tissue disorders/infections</p> <p>Renal</p>	<p><u>Only with rectal formulations:</u></p> <p>Anal discomfort</p> <p>Irritation at the application site</p> <p>Pruritus (anal)</p> <p>Tenesmus (rectal)</p> <p>Headache</p> <p>Idiopathic intracranial hypertension</p> <p>Anxiety</p> <p>Hypoesthesia</p> <p>Hypertension</p> <p>Diarrhea</p> <p>Abdominal pain</p> <p>Nausea</p> <p>Vomiting</p> <p>Gastroenteritis viral</p> <p>Flatulence</p> <p>Rash including urticaria, erythematous rash</p> <p>Exanthema</p> <p>Varicella</p> <p>Urinary Tract Infection</p>
Rare (> 0.01% and < 0.1%)	<p>Nervous system disorders</p> <p>Cardiac disorders</p> <p>Gastro-intestinal disorders</p> <p>Skin and subcutaneous tissue disorders/infections</p>	<p>Dizziness</p> <p>Myocarditis*</p> <p>Pericarditis*</p> <p>Increased amylase</p> <p>Acute pancreatitis*</p> <p>Photosensitivity**</p>
Very rare (< 0.01%)	<p>General disorders and administration site conditions</p>	<p>Drug fever</p>

Frequency of adverse effect	Organ system affected	Symptom
	Skin and subcutaneous tissue	Reversible alopecia Dermatitis allergic Erythema multiforme, and Stevens-Johnson Syndrome (SJS) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
	Hepato-biliary disorders	Increase in transaminases Cholestasis parameters (e.g. alkaline phosphatase, gamma-glutamyltransferase and bilirubin)
	Hepato-biliary disorders	Increase in transaminases Cholestasis parameters (e.g. alkaline phosphatase, gamma-glutamyltransferase and bilirubin) Hepatotoxicity (including hepatitis, cholestatic hepatitis*, cirrhosis, hepatic failure)
	Renal and urinary disorders	Nephropathy (renal function impairment, including interstitial nephritis*) Nephrotic syndrome Renal insufficiency Urine discoloration
	Reproductive system disorders	Oligospermia reversible
	Respiratory, thoracic and mediastinal disorders	Allergic and fibrotic lung reactions (including dyspnoea, coughing, bronchospasm, allergic alveolitis) Pulmonary eosinophilia Interstitial lung disease Pulmonary infiltration Pneumonitis /Bronchitis Pleurisy
	Musculo-skeletal, connective tissue and bone disorders	Myalgia Arthralgia Isolated reports of lupus-erythematosus-like syndrome (systemic lupus erythematosus)

Frequency of adverse effect	Organ system affected	Symptom
	Blood and lymphatic system disorders	Altered blood counts (anaemia, aplastic anaemia, agranulocytosis, neutropenia, leukopenia, including granulocytopenia, pancytopenia, thrombocytopenia and eosinophilia as part of an allergic reaction).
	Nervous system disorders	Peripheral neuropathy
	Immune system disorders	Hypersensitivity reaction including anaphylactic reaction
	Gastro-intestinal disorders	Pancolitis

* The mechanism of 5-ASA-induced myocarditis and pericarditis, pancreatitis, nephritis and hepatitis is unknown but may be of allergic origin. It is important to note that several of these disorders may also be attributable to the underlying inflammatory bowel disease itself.

** More severe reactions are reported in patients with pre-existing skin conditions such as atopic dermatitis and atopic eczema.

8.3. Less Common Clinical Trial Adverse Reactions

Cardiovascular:

Postural hypotension, tachycardia.

Dermatological:

Acne, alopecia, dry skin, eczema, erythema nodosum, erythematous rash, hirsutism, nail disorder, photosensitivity, pruritus, skin discoloration, sweating, Stevens-Johnson Syndrome (SJS), Toxic epidermal necrolysis (TEN).

Reversible alopecia has been reported in mesalazine-treated patients, as well as in placebo-treated patients, indicating that hair loss could be part of the underlying disease. Two cases of alopecia in patients on treatment with mesalazine at a dose of 4 g/day were confirmed by positive rechallenge. In one of the cases, the hair loss improved after dosage reduction to 2 g/day. However, the available data are insufficient to establish a dose relationship with mesalazine treatment generally.

Three cases of erythema nodosum have been reported in connection with PENTASA therapy. The causality was assessed as probable (1 case), possible (1 case) and not related (1 case) due to negative dechallenge. Erythema nodosum is a well-known extra-intestinal manifestation of inflammatory bowel disease.

Gastrointestinal:

Abdominal distension, anorexia, duodenal ulcer, eructation, esophageal ulcer, fecal incontinence, bloody stools or diarrhea, intestinal obstruction, melena, dysphagia, mouth ulcer, oral moniliasis, pancreatitis, rectal bleeding, rectal urgency, thirst.

Diarrhea is a commonly reported adverse event (about 3% frequency in clinical trials; somewhat less from spontaneous post-market surveillance reports), which is not dose-related. Diarrhea is also a symptom of the underlying disease and may indeed be indicative of inadequate dosage with PENTASA in some patients. Rarely mesalazine may exacerbate the inflammatory bowel disease itself.

It may be noted that melena has been reported as an adverse event rarely during mesalazine therapy, but it has not been definitely linked to treatment. Gastrointestinal bleeding has been assumed from observations of bloody diarrhea or stools. Again, blood in fecal matter may be a symptom of the underlying disease and has not been definitely linked to treatment.

Hematologic:

Agranulocytosis.

Immunological:

Anaphylactic reaction, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Metabolic:

Alkaline phosphatase increase, amylase increase, C reactive protein increase, creatinine increase, GGTP increase, LDH increase, proteinuria, SGOT increase, SGPT increase, weight decrease, weight increase.

Rise in liver enzymes by 3 to 5 times the normal range may be expected in a small percentage of patients treated with PENTASA. This variable and transient occurrence is difficult to relate definitely to drug treatment due to the concomitant drug therapy usual with patients, and due to enzyme fluctuations caused by the disease itself. In many cases, the enzyme increases resolve without drug discontinuation or reduction. In most cases, enzyme abnormalities are reversed on discontinuation of therapy. Rarely, increase in liver enzymes is indicative of developing hepatitis.

Similarly, increases in serum amylase and lipase levels by 3 to 5 times the normal range may occur, and are usually reversible upon dosage reduction or discontinuation. Very rarely, patients develop pancreatitis.

Weight loss is an expected consequence of inflammatory bowel disease. Weight gain is usually indicative of a positive clinical response to PENTASA therapy.

Nervous System:

Anxiety, abnormal dreams, dizziness, insomnia, somnolence, paraesthesia.

Renal/genitourinary:

Albuminuria, urinary frequency, urinary infection, urination disorder, vaginitis, isolated cases of nephrotic syndrome and interstitial nephritis. Cases of nephrolithiasis have been reported, however frequency cannot be estimated from the available data (see [7 Warnings and Precautions – Renal](#)).

Respiratory:

Dyspnea, increased coughing, pharyngitis.

Other:

Anemia, appetite decrease, arthralgia, breast pain, chest pain/pressure, chills, conjunctivitis, dry eyes, eye pain, ecchymosis, edema, eosinophilia, ESR increase, fatigue, fever, flu syndrome, leg cramps, malaise, menorrhagia, myalgia, scotoma, sore throat.

8.5. Post-Market Adverse Reactions

The following Post-Market Adverse Reactions have been seen with PENTASA and other mesalazine products.

Immune System Disorder: Anaphylactic reaction, drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN).

Nervous System Disorders: nephrolithiasis

Skin and Subcutaneous Tissue Disorders: photosensitivity, erythema multiforme

9. Drug Interactions

9.2. Drug Interactions Overview

There is a potential risk of myelosuppression, particularly leucopenia when aminosalicylates are co-administered with azathioprine or 6-mercaptopurine. Regular monitoring of white blood cells is recommended and dosage regime of thiopurines should be adjusted accordingly.

There is a potential risk of renal failure when aminosalicylates are co-administered with other nephrotoxic agents such as NSAIDs and azathioprine.

9.3. Drug-Behaviour Interactions

The interaction of PENTASA with individual behavioural risks (e.g. cigarette smoking, cannabis use, and/or alcohol consumption) has not been studied.

9.4. Drug-Drug Interactions

No investigations of interaction between PENTASA and other drugs have been performed. However, there have been reports of interactions between products containing mesalazine and other drugs. The concurrent use of mesalazine with known nephrotoxic agents, including non-steroidal anti-inflammatory drugs (NSAIDs) and azathioprine may increase the risk of renal reactions. In patients receiving azathioprine or 6-mercaptopurine, concurrent use of mesalazine can increase the potential for blood disorders, especially leucopenia.

Combination therapy with PENTASA and azathioprine, or 6-mercaptopurine or thioguanine have in several studies shown a higher frequency of myelosuppressive effects, and an interaction seems to exist, however, the mechanism behind the interaction is not fully established. Regular monitoring of white blood cells is recommended and dosage regime of thiopurines should be adjusted accordingly.

Caution should be exercised when mesalazine and sulfonyl ureas are prescribed concomitantly since the blood-sugar reducing effect of sulfonyl ureas may be enhanced. Interactions with coumarin, probenecid, sulfapyrazone, spironolactone, furosemide and rifampicin cannot be excluded. Mesalazine may delay the excretion of methotrexate.

There is weak evidence that mesalazine might decrease the anticoagulant effect of warfarin.

9.5. Drug-Food Interactions

The effect of food on the new formulation of PENTASA 500 mg extended release tablets has not been established. The new formulation was only administered under fed conditions (after a high fat meal) in a comparative bioavailability study comparing the new and former PENTASA extended release tablet formulations for safety purposes [for results see [14 Clinical Trials](#)]. In addition, PENTASA 500 mg extended release tablets were administered mainly with food, as part of an unrestricted diet in the pivotal phase 3 trial that was submitted for approval of the new PENTASA 500 mg extended release tablet formulation.

For this reason, PENTASA 500 mg extended release tablets should be taken with food. See [4 Dosage and Administration](#).

9.6. Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7. Drug-Laboratory Test Interactions

Several reports of possible interference with measurement, by liquid chromatography, of urinary normetanephrine causing a false-positive test result have been observed in patients exposed to sulfasalazine or its metabolite, mesalazine/mesalamine/5-ASA.

10. Clinical Pharmacology

10.1. Mechanism of Action

Mesalazine is an aminosalicylate, gastrointestinal anti-inflammatory agent. Aminosalicylates are considered to be one of the first line therapy(s) for inflammatory bowel diseases.

Mesalazine is the active component of sulfasalazine, which has been used for a long time in the treatment of ulcerative colitis and Crohn's disease.

The therapeutic value of mesalazine appears to be due to local effect on the inflamed intestinal tissue, rather than to systemic effect.

Increased leukocyte migration, abnormal cytokine production, increased production of arachidonic acid metabolites, particularly leukotriene B₄, and increased free radical formation in the inflamed intestinal tissue are all present in patients with inflammatory bowel disease. Mesalazine has in-vitro and in-vivo pharmacological effects that inhibit leukocyte chemotaxis, decrease cytokine and leukotriene production and scavenge for free radicals. The mechanism of action of mesalazine is, however, still not understood.

10.2. Pharmacodynamics

Regardless of its mode of action, mesalazine appears to exert its therapeutic effect by topical action on the affected areas of inflammation.

PENTASA tablets are composed of mesalazine extended-release granules that allows for a predictable, uniform, and continuous release of drug throughout the small (duodenum, jejunum and ileum) and large bowel (colon), at all enteral pH conditions. The release is not significantly compromised by diarrhea or increased bowel acidity, conditions which accompany active inflammatory bowel disease.

The PENTASA dosage forms designed for rectal administration, enemas and suppositories, are well suited to deliver the active ingredient, mesalazine, directly to affected areas along the mucosal lumen of the rectum, sigmoid and distal large bowel.

10.3. Pharmacokinetics

Oral Dosage Forms

Table 4 - Summary of Mesalazine Pharmacokinetic Parameters

	Single Dose		Steady State	
	C _{max} (ng/mL)	AUC ₀₋₂₄ (h·ng/mL)	C _{max} (ng/mL)	AUC ₀₋₂₄ (h·ng/mL)
Mesalazine				
2 g BID	5103.51	36,456	6803.70	57,519

Molecular weight of mesalazine: 153.13 g/mol; Ac-mesalazine: 195.17 g/mol

Absorption

Based on urinary excretion data, 20% to 30% of the mesalazine in PENTASA is absorbed. In contrast, when mesalazine is administered orally as an unformulated 1 g aqueous suspension, mesalazine is approximately 80% absorbed. Plasma mesalazine concentration peaked at approximately 1 µg/mL, three hours after a 1 g dose of PENTASA, and declined in a biphasic manner.

N-acetyl-5-ASA, the major metabolite of 5-ASA, peaked at approximately 3 hours at 1.8 µg/mL and its concentration followed a biphasic decline. Pharmacological activities of N-acetyl-5-ASA are unknown and other metabolites have not been identified.

Oral mesalazine pharmacokinetics were non-linear when PENTASA capsules were dosed from 250 mg to 1 g four times daily, with steady-state mesalazine plasma concentrations increasing about nine times, from 0.14 µg/mL to 1.21 µg/mL, suggesting saturable first-pass metabolism. N-acetyl-5-ASA pharmacokinetics was linear.

Co-administration of mesalazine tablets and a high fat meal was found to inhibit mesalazine and N-acetyl-5-ASA systemic absorption. Bioavailability of mesalazine decreased by about 70% and peak concentration decreased by about 60% as compared to the fasting state. N-acetyl-5-ASA pharmacokinetics was affected to a lesser extent, i.e., a 24% decrease in bioavailability and peak concentration. When food was present, less free mesalazine was eliminated in the feces (33%), although 15.2% more salicylates were eliminated in the feces than under fasting conditions. The same

effect was observed after administration of mesalazine in a suspension, indicating that the interaction involves mesalazine, not the PENTASA delivery system.

The effect of food on the new formulation of PENTASA 500 mg extended release tablets has not been established.

Distribution

Scintigraphic studies have shown that in the stomach, PENTASA extended release tablets disintegrate immediately into discrete extended release microgranules which are spread throughout the entire gastro-intestinal tract. The microgranules are emptied from the stomach within 17 ± 5 minutes under fasted conditions and within about 30 minutes when a breakfast meal is served 5 minutes post-dose. Therefore, the residence time in the stomach is not affected by post-dose food intake. The transit time through the small intestine has been shown to be 213 ± 45 minutes after which the microgranules arrive in the caecum. The small intestinal transit is not affected by post-dose food intake since no statistically significant difference could be detected between conditions in which subjects were fasted and those in which a meal was administered 5 minutes post-dose. The small intestinal transit time was 3.7 hours in fasted subjects and 3.1 hours in a fasted subject that had a breakfast meal 5 minutes post-dose. The microgranules reside in the colon for about 8 hours. The independence of food intake and intestinal transit has also been shown in another study, where the gastric emptying and small intestinal transit mesalazine microgranules occurred within the digestive period and synchronous with the meal.

Metabolism

Mesalazine is rapidly acetylated to N-acetyl-5-ASA. Pharmacological activities of N-acetyl-5-ASA are unknown and other metabolites have not been identified.

Elimination

In published single dose studies of PENTASA tablets, Rasmussen (1982) and Rijk (1988), both reported total combined fecal and urinary excretion to be 77% of total dose. Total fecal recovery varied slightly between reports. About 130 mg of free mesalazine was recovered in the feces following a single 1 g PENTASA dose. Forty-six percent of the dose was eliminated in the feces as mesalazine and N-acetyl-5-ASA. Elimination of free mesalazine and salicylates in feces increased proportionately with the dose of PENTASA. N-acetyl-5-ASA was the primary compound excreted in the urine (19% - 30%) following PENTASA dosing.

The literature describes a mean terminal half-life of 42 minutes for mesalazine following intravenous administration. Because of the continuous release and absorption of mesalazine from PENTASA throughout the gastrointestinal tract, the true elimination half-life cannot be determined after oral administration.

Rectal Dosage Forms

Absorption

The local and systemic bioavailability of PENTASA enema and PENTASA suppositories were assessed in 12 healthy volunteers under steady-state conditions. Systemic absorption of mesalazine was low. 15% of the 2 g daily dose was recovered in the urine (mostly as the acetylated metabolite) after administration of the enema, with 10% urinary recovery observed after administration of the suppositories. This compares to 20% to 30% of the mesalazine dose being absorbed systemically following oral administration.

Maximum plasma concentrations of mesalazine and of N-acetyl-5-ASA (approximately 0.7 µg/mL and 1.2 µg/mL respectively for the enema; 0.3 µg/mL and 0.8 µg/mL respectively for the suppositories) were reached 2 hours following administration of the enema and 5 to 6 hours following administration of the suppositories.

Local availability, as shown by recovery of free mesalazine in the feces, was higher for both the enema (mean 30%) and the suppositories (mean 45%) than for the oral dosage forms of mesalazine.

Bondesen et al. demonstrated that systemic absorption from mesalazine enemas was pH dependent, showing a significantly greater absorption at pH 7.4 (mean C_{max} in plasma 1.18 µg/mL for mesalazine, 0.55 µg/mL for N-acetyl-5-ASA) than at pH 4.8 (C_{max} 0.35 µg/mL for mesalazine, 0.55 µg/mL for N-acetyl-5-ASA). In another study, Bondesen et al demonstrated that systemic absorption of 5-ASA occurred to a similar degree in the right and the left parts of the colon, both being significantly lower than the absorption from the small intestine.

Systemic absorption of mesalazine was shown to be dose and volume dependent. Using a concentration of 4 g of mesalazine in 100 mL enema, Campieri et al. observed mean plasma levels of approximately 4 µg/mL for total (free and acetylated) mesalazine, which was approximately double of the level observed with 2 g of mesalazine enema. Systemic absorption was also increased when the volume of the enema was doubled, as shown by significant increase in urinary recovery. These same authors also showed that systemic absorption of mesalazine was significantly decreased in patients with active disease as compared to those in remission. They found no evidence of accumulation of total mesalazine in plasma after repeated daily administration of 2 g or 4 g enemas for 15 days to patients with active disease. This was also confirmed by Almer and collaborators with patients in remission, given 4 g enemas once a day for 7 days. Low systemic absorption of mesalazine from the suppository dosage form was also confirmed by Norlander et al. who found mean peak plasma levels of 0.2 µg/mL for mesalazine, 0.6 µg/mL for N-acetyl-5-ASA and urinary excretion of 10.8% (almost all as N-acetyl-5-ASA) following a single 500 mg dose of mesalazine given as a suppository to 12 healthy, fasting volunteers.

Distribution

The extent of colonic distribution of mesalazine was studied in patients with active left-sided ulcerative colitis, using scintigraphic imaging of ^{99m}Tc-labelled enemas and suppositories. These studies showed that the retrograde spread of mesalazine from 100 mL enemas, containing either 1 g or 4 g of the active compound, usually extended beyond the rectosigmoid, reliably reaching the areas of inflammation up to and including the splenic flexure. With the suppositories, the spread of ^{99m}Tc-labelled mesalazine was confined to the rectum and adjacent sigmoid colon, thereby acting on the inflamed mucosa in patients whose disease was localized in those areas.

Elimination

With regard to the clinically important local availability of free mesalazine, the values, measured in terms of fecal excretion, ranged from 26% (48-hour recovery) to 29.4% (24-hour recovery) and 30% (48-hour recovery), following administration of the enema and from 45% (48-hour recovery) to a high of 64.8% (72-hour recovery) following administration of suppositories. This compares to approximately 13% of the orally administered dose of mesalazine being excreted in the feces as free mesalazine.

11. Storage, Stability, and Disposal

Storage and Stability Information

PENTASA extended-release tablets (500 mg and 1 g) should be stored between 15°C and 30°C. Protect from light.

PENTASA rectal suspension (enema) and PENTASA suppositories should be stored at controlled room temperature, preferably below 25°C.

Disposal

They should be dispensed in their respective containers.

Keep out of the reach of children.

Part 2: Scientific Information

13. Pharmaceutical Information


Drug Substance

Non-proprietary name of the drug substance(s): 5-aminosalicylic acid (5-ASA)
mesalazine (INN)
mesalamine (USAN)

Chemical name: 2-hydroxy-5-aminobenzoic acid

Molecular formula and molecular mass: $C_7H_7O_3N$, 153.14 g/mol

Structural formula:



Product Characteristics:

Chemically, the medicinal ingredient of PENTASA (mesalazine) is 2-hydroxy-5-aminobenzoic acid. It is a white to tan coloured powder with a melting range of 283°C - 287°C. It is slightly soluble in cold water and alcohol, more soluble in hot water and soluble in hydrochloric acid. A saturated aqueous solution has a pH of 3.0 - 4.5 and a pK_a of 2.74.

14. Clinical Trials

14.1. Clinical Trials by Indication

Active Ulcerative Colitis and Ulcerative Colitis in Remission

Table 5 – Summary of Patient Demographics for Clinical Trials in Active Ulcerative Colitis and Ulcerative Colitis in Remission

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
CAMMP Study 2011	A multicentre, randomised, double-blind, non-inferiority trial comparing the efficacy and safety of a new modified oral extended release PENTASA® (mesalamine) 500 mg tablet to the currently marketed PENTASA® (mesalamine) 500 mg tablet.	Oral Tablets 4 g/day for 8 weeks (active)	N = 190 (active)	44.4 (18-68)	M = 59% F = 41%
		Oral Tablets 2g/day for 24 weeks (maintenance)	N = 153 (maintenance)	46.1 (20-76)	M = 56% F = 44%
Hanauer et al, 1993	Efficacy and Safety of PENTASA in the treatment of Acute exacerbations of Ulcerative Colitis	Oral Capsules 1g/day, 2g/day, 4g/day for 8 weeks	N = 374	40.1 (18+)	M = 51 % F = 49%

In an active-controlled, double-blind, non-inferiority, randomized trial (CAMMP study) patients with active mild to moderate ulcerative colitis were treated with PENTASA tablets 4 g/day for 8 weeks (active phase) and 2 g/ day for 24 weeks (maintenance phase).

Table 6 - Results of study CAMMP in Ulcerative Colitis (Induction and Maintenance of Remission)

Primary Endpoints	Associated value and statistical significance for Drug at specific dosages	Associated value and statistical significance for Placebo or active control
Active Phase Overall improvement at week 8: n/N (%)	50/78 (64.1%)	54/78 (69.2%)
Maintenance Phase Relapse before week 24: n/N (%)	15/61 (24.6%)	8/68 (11.8%)

Overall improvement is a complete remission or a clinical response to therapy as measured by the UCDAI. A relapse of UC is defined as a UCDAI score of ≥ 3 and an endoscopy score of ≥ 1 . The control arm using a former tablet formulation is not shown here. In the same CAMMP trial, at the end of the active phase (week 8), mucosal healing (endoscopic score =0) was observed in 47% of patients. However, this was one of many secondary endpoints, therefore, the interpretation of the results should be cautious.

In a placebo-controlled, double-blind, randomized trial of 374 patients with active mild to moderate ulcerative colitis, PENTASA, when given alone at total daily doses of 2 g to 4 g, improved the macroscopic appearance of the colonic mucosa and improved the physician’s overall clinical assessment of disease activity. The 4 g dose significantly improved the appearance of the colonic mucosa as assessed by histologic scoring. In addition, doses of 2 g or more relieved the predominant clinical symptoms that accompanied the active phase of ulcerative colitis by reducing the number of trips to the toilet, improving stool consistency, decreasing rectal bleeding, lessening rectal urgency, and reducing abdominal/rectal pain.

In a pivotal study of the PENTASA extended-release 5-ASA formulation compared to sulfasalazine therapy in patients with an established diagnosis of ulcerative colitis, but who had been in remission for between 1 month and 5 years, extended-release 5-ASA was demonstrated to be a safe and effective drug and equivalent to sulfasalazine in the maintenance of remission states. The ongoing remission rates after 6 and 12 months of treatment were 63% and 54% for the extended-release 5-ASA formulation, and 72% and 46% for sulfasalazine, respectively.

Table 7 - Summary of Patient Demographics for Clinical Trials in Crohn's Disease

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
Singleton et al, 1993	Efficacy and Safety of Oral PENTASA in the treatment of Active Crohn's Disease	Oral Capsules 1g/day, 2g/day, 4g/day for 16 weeks	N = 310	37 (16-76)	M = 36% F = 64%
Gendre et al, 1993	Oral Mesalamine (PENTASA) as Maintenance Treatment in Crohn's Disease: A Multicenter Placebo-Controlled Study	Oral-delayed release tablets 2g/day for 24 months	N = 161	33*	M = 47% F = 53%

*Patients older than 15 years were allowed to participate in this study

Results from two randomized, double-blind, placebo-controlled clinical trials involving 542 patients with Crohn's Disease, indicated that a daily dose of 4 g significantly reduced Crohn's Disease Activity Index (CDAI) compared to placebo. The mean (S.E.M.) decrease in CDAI from pre-treatment to study end was 53 (9) for the 4 g group compared to 22 (9) for the placebo group, a difference that was highly significant ($p=0.0114$).

In a randomized, double-blind, placebo-controlled trial conducted in 293 patients with Crohn's Disease in remission, a daily 3 g dose of PENTASA administered for a period of up to 48 weeks reduced the relapse rate (21% versus 41%; $p=0.018$) and increased the median time to relapse when compared with placebo.

Results from a meta-analysis (Messori et al, 1994) of nine randomized clinical trials (3 with the PENTASA formulation) also indicated that 5-ASA significantly reduced the frequency of relapse in patients with Crohn's Disease in remission. Pooled relapse-free rates in the treatment group were 84% and 72% at 1 and 2 years respectively; corresponding rates in the control group were 60% and 52%.

Table 8 - Summary of Patient Demographics for Clinical Trials in Active Proctitis and Distal Ulcerative Colitis*

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
Data on file at Ferring Pharmaceuticals PAPR0010	Efficacy and Safety of PENTASA Enema in the Treatment of Acute Exacerbations of Ulcerative Proctosigmoiditis	Rectal enema 1g, 2g, 4g nightly for 8 weeks	N = 287	40**	M = 25% F = 75%
Data on file at Ferring Pharmaceuticals PENSUP-90/01	A study of the efficacy of 1 g mesalazine suppositories in the treatment of mild to moderate ulcerative proctitis	Rectal suppository 1g nightly for 2 weeks	N = 50	44 (23-81)	M = 52% F = 48%

**Patients 18 years of age or greater were allowed to participate in this study.

The efficacy and safety of PENTASA enema were assessed in two multicentre, double-blind, randomized, controlled trials.

One of these trials compared the efficacy and safety of 1 g, 2 g and 4 g 5-ASA enemas against placebo during an 8-week period in patients with acute exacerbation of ulcerative proctosigmoiditis. This US study involved 287 randomized patients (70-73 per group). Efficacy was assessed in terms of clinical symptoms (including stool frequency, consistency, urgency, rectal bleeding and rectal/abdominal pain), macroscopic appearance of the affected mucosa (determined by sigmoidoscopy, scored from 0 to 15 according to vascular pattern, friability, presence of erythema, mucus/pus, granularity/ulcerations) and microscopic grading (0 for normal mucosa, 3 for high-grade, active, ulcerative inflammatory bowel disease) of the rectal biopsy specimens.

PENTASA enema was shown to be significantly ($p < 0.01$) superior to placebo in all efficacy parameters for each of the three doses. No dose-response relationship was demonstrated across the three PENTASA enema doses. All three doses were effective in inducing remission by at least one of the three remission parameters (physician's global assessment, sigmoidoscopic index, biopsy score): thus, 66% of the patients in the 1 g PENTASA enema group, 69% in the 2 g PENTASA enemas group and 74% in the 4 g PENTASA enema group achieved remission on this basis.

Safety in this multicentre trial was assessed by documenting all adverse events during treatment and from the results of laboratory tests. The type and frequency of adverse events reported for placebo and the three PENTASA enema doses were comparable (See [8 Adverse Reactions](#)).

PENTASA was discontinued in 4.6% of patients due to treatment-related adverse events, as compared to 5.7% of patients discontinued for the same reason in the placebo group. In addition, no significant changes in laboratory parameters were observed and there was no apparent cross-sensitivity in patients with known allergy to sulfasalazine.

In another multicentre, double-blind trial, conducted in Europe and involving 123 randomized patients with active mild to moderate proctosigmoiditis, PENTASA enema (1 g 5-ASA/100 mL) was tested against prednisolone enema (25 mg/100 mL) as active control for up to four-weeks duration of treatment. The criteria for evaluation of efficacy included grading of clinical symptoms (i.e. number of daily bowel movements, blood in stool, pus in stool, abdominal pain) and sigmoidoscopic scores. Remission was defined in terms of physician's assessments of clinical and sigmoidoscopic disease activities. Safety was assessed by documentation of adverse events and by the results of laboratory tests. At the end of the 28-day treatment period, overall favourable outcome, in terms of remission or improvement, was achieved by 77% of patients in the PENTASA group and by 72% of patients in the prednisolone group, the difference not being statistically significant. These results include 53% and 43% of patients in the PENTASA and prednisolone groups respectively, who showed both clinical and sigmoidoscopic remission. The adverse events observed were all mild and reversible and there was no statistically significant difference in their frequency between the two groups. No significant changes or abnormalities were observed in the following laboratory values: hemoglobin, reticulocytes, neutrophils, platelets, erythrocyte sedimentation rate, plasma orosomucoid, serum creatinine, urinary sediment and protein.

The clinical efficacy and safety of PENTASA 1 g suppositories were demonstrated in a multicentre, double-blind, randomized, placebo-controlled trial, involving 50 patients with active, mild to moderate ulcerative proctitis, for a two-week duration of treatment. Efficacy was assessed in terms of clinical symptoms (including daily stool frequency, presence of blood, discharge of mucus, rectal/abdominal pain) and proctoscopic scores. Clinical remission (defined as <4 stool frequency, absence of blood, mucus, rectal/abdominal pain) was achieved by 65.4% of patients in the PENTASA suppositories group vs. 25% in the placebo group ($p=0.005$). Proctoscopic remission, defined as absence of ulcerations or of bleeding either spontaneously or on contact, was reached by 69.2% of patients on PENTASA suppositories vs. 33.4% of patients on placebo ($p=0.05$). In this study, one patient in the PENTASA group experienced diarrhea on the first day of treatment only, whereas one patient in the placebo group experienced an increased frequency of bowel movements necessitating discontinuation of treatment.

The usefulness of PENTASA enema and suppositories for maintenance treatment and for preventing relapse of patients in remission from ulcerative colitis was also demonstrated by several investigators.

In one long-term study of up to 15 months duration, patients in remission received a 4 g PENTASA enema every other day, at bedtime. The dose could be tapered (i.e. the dosing frequency reduced) with the approval of both investigators and patient. On this regimen, 12 of 15 patients (80.0%), who were treated for 12 months, were maintained in remission.

In another, randomized, double-blind, placebo-controlled study, nine of twelve (75.0%) patients randomized to receive 1 g mesalazine enema/day remained in remission for one year. The difference between relapse rate on 1 g 5-ASA enema (25.0%) versus placebo (84.6%) was significant ($p<0.005$).

In their study, Guarino and collaborators examined the role of 4 g mesalazine enema in the long-term management of patients with previously refractory distal ulcerative colitis. Of 20 such patients treated with nightly mesalazine enemas, 16 improved symptomatically, with 15 achieving clinical remission and 14 achieving sigmoidoscopic remission within 3 to 5 weeks. These authors showed, by following up

patients for up to 16 months, that, once remission is achieved, patients can be well managed with continued use of 4 g mesalazine enemas at less-than-nightly intervals and prompt reinstatement of nightly enemas in case of disease flare-ups.

Using 1 g mesalazine suppositories in a once-a-day regimen, Campieri and co-workers succeeded in maintaining 10 of 19 patients (53%) in remission from distal ulcerative colitis for 6 months.

14.2. Comparative Bioavailability Studies

Oral Dosage Form:

One single-dose, randomized, double-blinded, two-way crossover comparative bioavailability study, conducted under fed conditions, was performed on healthy male and female volunteers. The rate and extent of absorption of 5-acetylsalicylic acid was measured and compared following a single oral dose (1 x 500 mg) of PENTASA 500 mg extended-release tablets (new formulation) and PENTASA 500 mg extended-release tablets (former formulation). The results from a total of sixty-three (63) volunteers are summarized in Table 9.

Table 9 - Summary of the Comparative Bioavailability Data

5-aminosalicylic acid (1 x 500 mg extended-release tablet) From measured data Least Squares Mean Arithmetic Mean (CV %)				
Parameter	Test ¹	Reference ²	% Ratio of Least Squares Mean	90% Confidence Interval
AUC _T (ng h/mL)	858.97 1166.17 (97.33)	798.10 973.32 (60.91)	107.6	90.9 – 127.4
AUC _∞ ³ (ng h/mL)	923.99 1260.17 (95.99)	853.39 1049.42 (55.83)	108.3	87.4 – 134.2
C _{MAX} (ng/mL)	348.19 535.33 (107.58)	305.24 421.29 (81.94)	114.1	92.3 – 141.1
T _{MAX} ⁴ (h)	4.50 (2.00 – 12.00)	4.50 (2.50 – 13.00)		
T _½ ^{3,5} (h)	1.28 (59.78)	1.81 (109.15)		

¹PENTASA (5-ASA) 500 mg extended release tablets (New formulation)

²PENTASA (5-ASA) 500 mg extended release tablets (Old formulation)

³Calculated for 48/63 subjects (Test) and 47/63 subjects (Reference) only

⁴Expressed as the median (range) only

⁵Expressed as the arithmetic mean (CV%) only

15. Microbiology

No microbiological information is required for this drug product.

16. Non-Clinical Toxicology

General toxicology

The kidney appears to be the major target organ for mesalazine toxicity in animal studies. No significant toxicities associated with the gastrointestinal tract, liver, or hematopoietic system in animals have been observed.

In the acute toxicity study in pigs, using single oral doses of up to 5 g/kg body weight, no deaths were observed. Single intravenous doses of 920 mg/kg in rats were not fatal.

In 13-week oral studies, no toxic effects were seen at 2400 mg/kg/day in the mouse and 480 mg/kg/day in the rat. Renal lesions including granular and hyaline casts, tubular degeneration, tubular dilation, renal infarct, papillary necrosis, and renal tubular necrosis, were observed in mice at 4000 mg/kg/day and rats at 2770 mg/kg/day. Minimal degrees of papillary necrosis and tubular degeneration were found in male rats at 1150 mg/kg/day. Chronic (1-year) administration to rats at doses greater than or equal to 1200 mg/kg/day resulted in papillary necrosis and interstitial nephritis; 800 mg/kg/day was a “no observable effect” dose.

A 13-week study in monkeys demonstrated renal toxicity at doses of 500 mg/kg/day. Renal lesions included interstitial fibrosis and corticomedullary edema without evidence of active nephritis. Monkeys treated with doses of 125 and 250 mg/kg/day experienced no adverse renal effects. A 1-year chronic study in monkeys produced nephrosis with doses of 250 mg/kg/day and 500 mg/kg/day.

Genotoxicity

No evidence of mutagenicity was observed in a microbial mutagen test using mutant strains of *Salmonella typhimurium* with and without metabolic activation. A micronucleus test in mice also indicated that PENTASA was not mutagenic.

Reproductive and developmental toxicology

No effects on fertility or reproductive performance were observed in male or female rats at doses up to 400 mg/kg/day (seven times the maximum human dose). Reproduction studies have been performed in rats and rabbits at doses up to seventeen times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to mesalazine.

Preclinical toxicology studies used unformulated mesalazine, which, when administered orally, has a greater systemic absorption than formulated PENTASA. The therapeutic dose of mesalazine in humans is approximately 30 mg/kg/day to 60 mg/kg/day.

Patient Medication Information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

P^rPENTASA[®]

Mesalazine extended release tablets

This Patient Medication Information is written for the person who will be taking **PENTASA**. This may be you or a person you are caring for. Read this information carefully. Keep it as you may need to read it again.

This Patient Medication Information is a summary. It will not tell you everything about this medication. If you have more questions about this medication or want more information about **PENTASA**, talk to a healthcare professional.

What PENTASA is used for:

- PENTASA tablets are used in adults for the treatment of Ulcerative Colitis or Crohn's Disease. PENTASA tablets can also be used long-term in both of these conditions to help maintain remission and prevent relapse.
- Ulcerative Colitis is a disease of the large bowel (colon) and rectum (the last 6 inches of the large intestine), where the lining of the gut becomes red and swollen (inflamed) resulting in symptoms of frequent and bloody stools together with stomach cramps.
- Crohn's Disease is a form of inflammatory bowel disease (IBD). It usually affects the intestines, but may occur anywhere from the mouth to the end of the rectum (anus).

How PENTASA works:

It is believed that PENTASA blocks the production and action of certain substances involved in producing inflammation. PENTASA passes throughout the colon and rectum to treat this inflammation and reduce symptoms, such as bloody stools and diarrhea.

The ingredients in PENTASA are:

Medicinal ingredients: mesalazine (also known as mesalamine, 5-ASA or 5-aminosalicylic acid).

Non-medicinal ingredients: ethylcellulose, magnesium stearate, microcrystalline cellulose, povidone and talc.

PENTASA tablets do not contain gluten, lactose or phthalates.

PENTASA comes in the following dosage form(s):

Extended-release tablets: 500 mg, 1 g

Do not use PENTASA if:

- you are allergic to mesalazine / mesalamine or any of the non-medicinal ingredients in PENTASA or parts of the container
- you are allergic to a family of drugs known as salicylates, which includes acetylsalicylic acid (ASA)
- you have severe liver problems
- you have severe kidney problems
- you have a stomach or intestinal ulcer
- you have a blockage of your urinary tract
- the patient is an infant under 2 years of age

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take PENTASA. Talk about any health conditions or problems you may have, including if you:

- have pyloric stenosis (a narrowing of the outlet from the stomach that causes contents of the stomach to remain there for a longer period of time)
- have any kidney or liver problems
- have digestive (peptic) ulcers
- have heart problems, including a history of heart inflammation (which may have been the result of an infection of the heart)
- have chronic lung problems (e.g. asthma, bronchitis)
- have had an allergic (hypersensitivity) reaction to sulfasalazine (an ingredient in other medicines used to treat Ulcerative Colitis)

Other warnings you should know about:

Serious Side Effects: PENTASA can cause serious side effects:

- **Serious skin reactions:** Severe cutaneous adverse reactions (SCAR), including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have happened in people taking PENTASA. These skin reactions are serious. Stop taking PENTASA and get immediate medical help if you experience any signs of a severe skin reaction, such as mouth sores or a severe skin rash, or any other signs of an allergic reaction.
- **Kidney problems, including kidney stones:** People taking PENTASA can develop kidney stones and other kidney problems. Symptoms may include blood in the urine, urinating more often, pain in your back, side, belly or groin. Be sure to drink enough liquids while you are taking PENTASA. Talk to your healthcare professional about how much water or other liquids you should be drinking.
- **Acute Intolerance Syndrome:** Symptoms of acute intolerance syndrome can be similar to a flare of IBD. If you think you are experiencing a flare of your condition, talk to your healthcare professional immediately.
- **Heart problems:** These include inflammation of the heart muscle (myocarditis) and inflammation of the tissue around the heart (pericarditis).
- **Blood problems:** This includes a complete lack of blood cells (myelosuppression).
- **Liver problems:** This included liver failure.

Pregnancy and Breastfeeding:

- Talk to your healthcare professional if you are pregnant or thinking of becoming pregnant. PENTASA may have an effect on your unborn baby. Some babies born to mothers who took PENTASA while they were pregnant were born with blood disorders.
- You should not breastfeed while you are taking PENTASA. PENTASA passes into breastmilk.
- If you breastfeed your baby while taking PENTASA your baby could develop / start to have diarrhea. It is important to monitor your baby's stool and contact your healthcare professional right away if they have diarrhea. Your healthcare professional may advise you to stop breastfeeding your baby.

Male fertility: Men taking PENTASA have experienced decreased sperm count and sperm mobility. Talk to your healthcare professional if you would like more information about the possible effects of PENTASA on your fertility.

Blood tests: PENTASA can cause abnormal blood test results. Your healthcare professional will do blood tests before you start taking PENTASA and periodically during treatment. They will check the health of your liver and kidneys as well as the levels of your red and white blood cells and monitor you for other side effects. Your healthcare professional will decide when to perform blood tests and will interpret the results.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with PENTASA:

- anti-inflammatory drugs (NSAIDS), used to treat pain and inflammation
- other medicines used to treat Ulcerative Colitis and Crohn's Disease such as azathioprine, 6-mercaptopurine
- anticoagulants, used to thin the blood and prevent blood clots such as coumarin, warfarin
- medicines used to treat gout, such as probenecid, sulfinpyrazone
- medicines used to treat high blood pressure, such as spironolactone, furosemide
- medicines used to treat cancer, such as methotrexate, thioguanine
- rifampicin, an antibiotic used to treat bacterial infections

How to take PENTASA:

- Always take PENTASA as directed by your healthcare professional.
- PENTASA tablets should not be chewed, broken or crushed but should be swallowed whole with plenty of water.
- PENTASA tablets should be taken with meals.

Usual dose:

Adults:

Ulcerative Colitis: 500 mg four times daily (2 g daily dose). In some cases, your healthcare professional may increase the dose up to 1 g four times daily (4 g daily dose) if required.

Crohn's Disease: 1 g four times daily (4 g daily dose). For patients in remission a daily dose of 3 g in divided doses is recommended.

Overdose:

If you think you, or a person you are caring for, have taken too much PENTASA, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed dose:

If you forget to take a dose, skip the missed dose, then take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose.

Possible side effects from using PENTASA:

These are not all the possible side effects you may have when taking PENTASA. If you experience any side effects not listed here, tell your healthcare professional.

Side effects may include:

- abdominal pain
- vomiting, nausea
- diarrhea
- gas
- rash, itching skin
- dry, cracked skin rash with oozing and crusting (dermatitis)
- chicken pox
- fatigue
- fever
- back pain
- muscle and joint pain
- dizziness
- headache
- urine discoloration
- hair loss
- anxiety
- numbness, tingling or burning in the hands or feet

Serious side effects and what to do about them

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
Common			
Urinary tract infection: strong, persistent urge to urinate, pain or burning when urinating, bloody, cloudy or strong smelling urine, passing frequent, small amounts of urine		√	
High blood pressure: headaches, shortness of breath, nosebleeds		√	
Rare			
Blood problems: unexplained bruising, unusual bleeding, nose bleeds, bleeding of the gums or mouth, tiny red spots on the skin, rash, shortness of breath, pale skin, lips and nail beds, weakness, fatigue, infections (fever, chills, sore throat, mouth sores)		√	
Pancreatitis (inflamed or swollen pancreas): abdominal pain that lasts and gets worse when you lie down, nausea, vomiting		√	
Acute Intolerance Syndrome: cramping, acute stomach pain, bloody diarrhea, fever, headache			√
Serious skin reactions (Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), erythema multiforme): skin peeling, scaling, or blistering which may also affect your eyes, mouth, nose, genitals hands or the soles of your feet, itching, severe rash, skin pain, skin color changes (redness, yellowing, purplish), swelling and redness of eyes or face, flu-like feeling, joint pain, fatigue, fever, chills, body aches, swollen glands, cough			√
Kidney stones (hard little pebbles that form in your kidneys): blood in		√	

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
urine, urinating more often, pain in your back, side, belly or groin			
Allergic reaction: rash, hives, swelling of the mouth, throat, difficulty swallowing or breathing			√
Liver problems (including liver failure): yellowing of the skin and eyes, dark urine, pale stool, abdominal pain, nausea, vomiting, loss of appetite		√	
Heart Problems (including pericarditis and myocarditis or heart inflammation): chest pain, fast or irregular heartbeat, shortness of breath			√
Photosensitivity (sensitivity of the skin to the sun): rash, redness, blisters, itching and burning when the skin is exposed to the sun or UV light	√		
Very rare			
Kidney problems: decreased urination, nausea, vomiting, swelling of extremities, fatigue		√	
Lupus-erythematosus-like syndrome: pain and swelling in the joints, skin rash, fatigue, fever		√	
Lung problems: trouble breathing, wheezing, dry cough, chills, sweating, body aches, fatigue		√	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store at room temperature (15°C to 30°C). Protect from light.

Keep out of reach and sight of children.

If you want more information about PENTASA:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database website ([Drug Product Database: Access the database](#)); Ferring Inc.'s website: www.ferring.ca, or by calling 1-866-384-1314.

This leaflet was prepared by



Date of Authorization: 2026-04-16

® Registered Trademark of Ferring BV

Patient Medication Information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

P^rPENTASA[®]


Mesalazine rectal suspension

This Patient Medication Information is written for the person who will be taking **PENTASA**. This may be you or a person you are caring for. Read this information carefully. Keep it as you may need to read it again.

This Patient Medication Information is a summary. It will not tell you everything about this medication. If you have more questions about this medication or want more information about **PENTASA**, talk to a healthcare professional.

What PENTASA is used for:

- PENTASA rectal suspension (enema) is used in adults for treatment of acute distal Ulcerative Colitis. PENTASA enemas can also be used for long-term maintenance therapy to help maintain remission and prevent relapse.
- Ulcerative Colitis occurs in the large bowel. Distal Ulcerative Colitis occurs in the last part of the bowel, from the rectum up to the splenic flexure, shown by the dark shaded area in the image below.



How PENTASA works:

It is believed that PENTASA blocks the production and action of certain substances involved in producing inflammation. PENTASA enemas allow the medicine to directly cover the affected tissue in the colon and rectum to treat this inflammation and reduce symptoms, such as bloody stools and diarrhea.

The ingredients in PENTASA are:

Medicinal ingredients: mesalazine (also known as mesalamine, 5-ASA or 5-aminosalicylic acid).

Non-medicinal ingredients: hydrochloric acid (to adjust pH), purified water, sodium acetate, sodium edetate, sodium metabisulfite.

PENTASA is phthalate free.

PENTASA comes in the following dosage form(s):

Rectal suspension (enema): 1g per 100 mL and 4g per 100 mL

Do not use PENTASA if:

- you are allergic to mesalazine / mesalamine or any of the non-medicinal ingredients in PENTASA or parts of the container
- you are allergic to a family of drugs known as salicylates, which includes acetylsalicylic acid (ASA)
- you have severe liver problems
- you have severe kidney problems
- you have a stomach or intestinal ulcer
- you have a blockage of your urinary tract
- the patient is an infant under 2 years of age

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take PENTASA. Talk about any health conditions or problems you may have, including if you:

- have pyloric stenosis (a narrowing of the outlet from the stomach that causes contents of the stomach to remain there for a longer period of time)
- have any kidney or liver problems
- have digestive (peptic) ulcers
- have heart problems, including a history of heart inflammation (which may have been the result of an infection of the heart)
- have chronic lung problems (e.g. asthma, bronchitis)
- have had an allergic (hypersensitivity) reaction to sulfasalazine (an ingredient in other medicines used to treat Ulcerative Colitis)

Other warnings you should know about:

Serious Side Effects: PENTASA can cause serious side effects:

- **Serious skin reactions:** Severe cutaneous adverse reactions (SCAR), including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have happened in people taking PENTASA. These skin reactions are serious and can be fatal. Stop taking PENTASA and get immediate medical help if you experience any signs of a severe skin reaction, such as mouth sores or a severe skin rash, or any other signs of an allergic reaction.
- **Kidney problems, including kidney stones:** People taking PENTASA can develop kidney stones and other kidney problems. Symptoms may include blood in the urine, urinating more often, pain in your back, side, belly or groin. Be sure to drink enough liquids while you are taking PENTASA. Talk to your healthcare professional about how much water or other liquids you should be drinking.
- **Acute Intolerance Syndrome:** Symptoms of acute intolerance syndrome can be similar to a flare of IBD. If you think you are experiencing a flare of your condition, talk to your healthcare professional immediately.
- **Heart problems:** These include inflammation of the heart muscle (myocarditis) and inflammation of the tissue around the heart (pericarditis).
- **Blood problems:** This includes a complete lack of blood cells (myelosuppression).
- **Liver problems:** This included liver failure.

Pregnancy and Breastfeeding:

- Talk to your healthcare professional if you are pregnant or thinking of becoming pregnant. PENTASA may have an effect on your unborn baby. Some babies born to mothers who took PENTASA while they were pregnant were born with blood disorders.
- You should not breastfeed while you are taking PENTASA. PENTASA passes into breastmilk.
- If you breastfeed your baby while taking PENTASA your baby could develop / start to have diarrhea. It is important to monitor your baby's stool and contact your healthcare professional right away if they have diarrhea. Your healthcare professional may advise you to stop breastfeeding your baby.

Male fertility: Men taking PENTASA have experienced decreased sperm count and problems with sperm motility. Talk to your healthcare professional if you would like more information about the possible effects of PENTASA on your fertility.

Blood tests: PENTASA can cause abnormal blood test results. Your healthcare professional will do blood tests before you start taking PENTASA and periodically during treatment. They will check the health of your liver and kidneys as well as the levels of your red and white blood cells and monitor you for other side effects. Your healthcare professional will decide when to perform blood tests and will interpret the results.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with PENTASA:

- anti-inflammatory drugs (NSAIDs), used to treat pain and inflammation
- other medicines used to treat Ulcerative Colitis and Crohn's Disease such as azathioprine, 6-mercaptopurine
- anticoagulants, used to thin the blood and prevent blood clots such as coumarin, warfarin
- medicines used to treat gout, such as probenecid, sulfinpyrazone
- medicines used to treat high blood pressure, such as spironolactone, furosemide
- medicines used to treat cancer, such as methotrexate, thioguanine
- rifampicin, an antibiotic used to treat bacterial infections

How to take PENTASA:

- Always take PENTASA as directed by your healthcare professional. Your healthcare professional will tell you how long to take PENTASA. Talk to your healthcare professional if you are unsure.
- You should empty your bowel, if possible, before administering the PENTASA enema.


Usual Dose:

Adults: One enema nightly, at bedtime. Retain the enema overnight for best results.

Directions for Adult Use

1. Removing the bottle

Remove the bottle from the protective foil pouch by using scissors as shown below. Be careful not to puncture the bottle inside.




The enema should be used immediately after opening of the bag.

Preparing the medication for use

- a. Begin by holding the bottle for a few minutes. Doing this raises the temperature of the medication closer to your body temperature. This will reduce the temperature shock you might experience and make it easier to retain the enema.
- b. Shake the bottle well until the medicine is evenly distributed in the liquid.




- c. To break the seal, twist the nozzle clockwise one full turn (the nozzle should then be in the same direction as before turning).



- d. Lubricate the top part of the rectal applicator, including the tip, with petroleum jelly (or other lubricant).
- e. For sanitary and disposal purposes, a plastic bag is provided. Insert your hand into the bag and grasp the enema bottle.




- f. Hold the container as shown in the picture.




2. Administrating the enema

- a. To administer the enema, lie on your left side with the left leg straight and the right leg bent forward for balance. This is called the **administration position**.
- b. Carefully insert the applicator tip into the rectum. Maintain sufficient steady hand pressure while dispersing the bottle contents. It should take you a maximum of 30-40 seconds to insert the entire contents of the bottle into your rectum.




3. Disposal of the enema bottle

- a. Once the bottle is empty, withdraw the tip with the bottle still compressed.
- b. Pull the plastic bag up and over the bottle to encase the empty enema bottle.
- c. The enema should be retained in the bowel. Remain relaxed in the **administration position** for 5-10 minutes or until the urge to pass the enema has disappeared. Try to retain the enema overnight.



- d. Discard the empty bagged enema bottle and wash your hands.



Overdose:

If you think you, or a person you are caring for, have taken too much PENTASA, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed dose:

If you forget to take your dose before bedtime, take it as soon as you remember IF you will be able to retain the enema. If this is not possible, skip the missed dose and go back to your regular dosing schedule the next night at bedtime.

Possible side effects from using PENTASA:

These are not all the possible side effects you may have when taking PENTASA. If you experience any side effects not listed here, tell your healthcare professional.

Side effects may include:

- anal discomfort
- irritation where you have inserted PENTASA
- feeling the urge to have a bowel movement
- excessive gas
- abdominal pain
- vomiting, nausea
- diarrhea
- rash, itching skin
- dry, cracked skin rash with oozing and crusting (dermatitis)
- chicken pox
- fatigue
- fever
- back pain
- muscle and joint pain
- dizziness
- headache
- urine discolouration
- hair loss
- anxiety
- numbness, tingling or burning in the hands or feet

Serious side effects and what to do about them

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
Common			
Urinary tract infection: strong, persistent urge to urinate, pain or burning when urinating, bloody, cloudy or strong smelling urine, passing frequent, small amounts of urine		√	
High blood pressure: headaches, shortness of breath, nosebleeds		√	
Rare			
Blood problems: unexplained bruising, unusual bleeding, nose bleeds, bleeding of the gums or mouth, tiny red spots on the skin, rash, shortness of breath, pale skin, lips and nail beds, weakness, fatigue, infections (fever, chills, sore throat, mouth sores)		√	
Pancreatitis (inflamed or swollen pancreas): abdominal pain that lasts and gets worse when you lie down, nausea, vomiting		√	
Acute Intolerance Syndrome: cramping, acute stomach pain, bloody diarrhea, fever, headache			√
Serious skin reactions (Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), erythema multiforme): skin peeling, scaling, or blistering which may also affect your eyes, mouth, nose, genitals hands or the soles of your feet, itching, severe rash, skin pain, skin color changes (redness, yellowing, purplish), swelling and redness of eyes or face, flu-like feeling, joint pain, fatigue, fever, chills, body aches, swollen glands, cough			√
Kidney stones (hard little pebbles that form in your kidneys): blood in		√	

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
urine, urinating more often, pain in your back, side, belly or groin			
Allergic reaction: rash, hives, swelling of the mouth, throat, difficulty swallowing or breathing			√
Liver problems (including liver failure): yellowing of the skin and eyes, dark urine, pale stool, abdominal pain, nausea, vomiting, loss of appetite		√	
Heart problems (including pericarditis and myocarditis or heart inflammation): chest pain, fast or irregular heartbeat, shortness of breath			√
Photosensitivity (sensitivity of the skin to the sun): rash, redness, blisters, itching and burning when the skin is exposed to the sun or UV light	√		
Very rare			
Kidney problems: decreased urination, nausea, vomiting, swelling of extremities, fatigue		√	
Lupus-erythematosus-like syndrome: pain and swelling in the joints, skin rash, fatigue, fever		√	
Lung problems: trouble breathing, wheezing, dry cough, chills, sweating, body aches, fatigue		√	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

PENTASA rectal suspension (enema) should be stored at room temperature, below 25°C. It should be kept in the original container until ready to use.

Keep out of reach and sight of children.

If you want more information about PENTASA:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database website ([Drug Product Database: Access the database](#)); Ferring Inc.'s website www.ferring.ca, or by calling 1-866-384-1314.

This leaflet was prepared by



Date of Authorization: 2026-04-16

®Registered Trademark of Ferring BV

Patient Medication Information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

P^rPENTASA[®]


Mesalazine suppository

This Patient Medication Information is written for the person who will be taking PENTASA. This may be you or a person you are caring for. Read this information carefully. Keep it as you may need to read it again.

This Patient Medication Information is a summary. It will not tell you everything about this medication. If you have more questions about this medication or want more information about PENTASA, talk to a healthcare professional.

What PENTASA is used for:

- PENTASA suppositories are used in adults for the treatment of acute Ulcerative Proctitis. PENTASA suppositories can also be used for long-term maintenance therapy to help maintain remission and prevent relapse.
- Acute Ulcerative Proctitis is an inflammation of the lining of the rectum. The rectum is the last 6 inches of the large intestine.



How PENTASA works:

It is believed that PENTASA blocks the production and action of certain substances involved in producing inflammation. PENTASA suppositories allow the medicine to directly cover the affected tissue in the rectum to treat this inflammation and reduce symptoms, such as bloody stools and diarrhea.

The ingredients in PENTASA are:

Medicinal ingredients: mesalazine (also known as mesalamine, 5-ASA or 5-aminosalicylic acid).

Non-medicinal ingredients: magnesium stearate, polyethylene glycol, povidone, talc

PENTASA is phthalate free.

PENTASA comes in the following dosage forms:

Suppository: 1 g

Do not use PENTASA if:

you are allergic to mesalazine / mesalamine or any of the non-medicinal ingredients in PENTASA or parts of the container

- you are allergic to a family of drugs known as salicylates, which includes acetylsalicylic acid (ASA)
- you have severe liver problems
- you have severe kidney problems
- you have a stomach or intestinal ulcer
- you have a blockage of your urinary tract
- the patient is an infant under 2 years of age

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take PENTASA. Talk about any health conditions or problems you may have, including if you:

- have pyloric stenosis (a narrowing of the outlet from the stomach that causes contents of the stomach to remain there for a longer period of time)
- have any kidney or liver problems
- have digestive (peptic) ulcers
- have heart problems, including a history of heart inflammation (which may be the result of an infection of the heart)
- have chronic lung problems (e.g. asthma, bronchitis)
- have had an allergic (hypersensitivity) reaction to sulfasalazine (an ingredient in other medicines used to treat Ulcerative Colitis)

Other warnings you should know about:

Serious Side Effects: PENTASA can cause serious side effects:

- **Serious skin reactions:** Severe cutaneous adverse reactions (SCAR), including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have happened in people taking PENTASA. These skin reactions are serious. Stop taking PENTASA and get immediate medical help if you experience any signs of a severe skin reaction, such as mouth sores or a severe skin rash, or any other signs of an allergic reaction.
- **Kidney problems, including kidney stones:** People taking PENTASA can develop kidney stones and other kidney problems. Symptoms may include blood in the urine, urinating more often, pain in your back, side, belly or groin. Be sure to drink enough liquids while you are taking PENTASA. Talk to your healthcare professional about how much water or other liquids you should be drinking
- **Acute Intolerance Syndrome:** Symptoms of acute intolerance syndrome can be similar to a flare of IBD. If you think you are experiencing a flare of your condition, talk to your healthcare professional immediately.
- **Heart problems:** These include inflammation of the heart muscle (myocarditis) and inflammation of the tissue around the heart (pericarditis).
- **Blood problems:** This includes a complete lack of blood cells (myelosuppression).
- **Liver problems:** This included liver failure.

Pregnancy and Breastfeeding:

- Talk to your healthcare professional if you are pregnant or thinking of becoming pregnant. PENTASA may have an effect on your unborn baby. Some babies born to mothers who took PENTASA while they were pregnant were born with blood disorders.
- You should not breastfeed while you are taking PENTASA. PENTASA passes into breastmilk.
- If you breastfeed your baby while taking PENTASA your baby could develop / start to have diarrhea. It is important to monitor your baby's stool and contact your healthcare professional right away if they have diarrhea. Your healthcare professional may advise you to stop breastfeeding your baby.

Male fertility: Men taking PENTASA have experienced decreased sperm count and sperm mobility. Talk to your healthcare professional if you would like more information about the possible effects of PENTASA on your fertility.

Blood tests: PENTASA can cause abnormal blood test results. Your healthcare professional will do blood tests before you start taking PENTASA and periodically during treatment. They will check the health of your liver and kidneys as well as the levels of your red and white blood cells and monitor you for other side effects. Your healthcare professional will decide when to perform blood tests and will interpret the results.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with PENTASA:

- anti-inflammatory drugs (NSAIDS), used to treat pain and inflammation
- other medicines used to treat Ulcerative Colitis and Crohn's Disease such as azathioprine, 6-mercaptopurine
- anticoagulants, used to thin the blood and prevent blood clots such as coumarin, warfarin
- medicines used to treat gout, such as probenecid, sulfinpyrazone
- medicines used to treat high blood pressure, such as spironolactone, furosemide
- medicines used to treat cancer, such as methotrexate, thioguanine
- rifampicin, an antibiotic used to treat bacterial infections

How to take PENTASA:

- Take PENTASA as directed by your healthcare professional. Your healthcare professional will tell you how long to take PENTASA. Talk to your healthcare professional if you are unsure.
- You should empty your bowel, if possible, before inserting the PENTASA suppository.
- Push the suppository through the foil blister.
- You may lubricate the suppository with a water based lubricant to make it easier to insert.
- Using a rubber finger protector on your index finger, insert the suppository, either end first, into the rectum. You can insert the suppository while in a standing position or while laying down with one leg bent. The suppository should be inserted as far into the rectum as possible.
- The suppository should be kept in the rectum for as long as possible. If the suppository comes in within the first 10 minutes, a new one can be inserted.
- After inserting the suppository, discard the rubber finger protector and wash your hands.

Usual dose:

Adults: One suppository nightly, at bedtime.

Overdose:

If you think you, or a person you are caring for, have taken too much PENTASA, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed dose:

If you forget to take your dose before bedtime, take it as soon as you remember IF you will be able to retain the suppository. If this is not possible, skip the missed dose and go back to your regular dosing schedule the next night at bedtime.

Possible side effects from using PENTASA:

These are not all the possible side effects you may have when taking PENTASA. If you experience any side effects not listed here, tell your healthcare professional.

Side effects may include:

- anal discomfort
- irritation where you have inserted PENTASA
- feeling the urge to have a bowel movement
- excessive gas
- abdominal pain
- vomiting, nausea
- diarrhea
- rash, itching skin
- dry, cracked skin rash with oozing and crusting (dermatitis)
- chicken pox
- fatigue
- fever
- back pain
- muscle and joint pain
- dizziness
- headache
- urine discolouration
- hair loss
- anxiety
- numbness, tingling or burning in the hands or feet

Serious side effects and what to do about them

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
Common			
Urinary tract infection: strong, persistent urge to urinate, pain or burning when urinating, bloody, cloudy or strong smelling urine, passing frequent, small amounts of urine		√	
High blood pressure: headaches, shortness of breath, nosebleeds		√	
Rare			
Blood problems: unexplained bruising, unusual bleeding, nose bleeds, bleeding of the gums or mouth, tiny red spots on the skin, rash, shortness of breath, pale skin, lips and nail beds, weakness, fatigue, infections (fever, chills, sore throat, mouth sores)		√	
Pancreatitis (inflamed or swollen pancreas): abdominal pain that lasts and gets worse when you lie down, nausea, vomiting		√	
Acute Intolerance Syndrome: cramping, acute stomach pain, bloody diarrhea, fever, headache			√
Serious skin reactions (Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), erythema multiforme): skin peeling, scaling, or blistering which may also affect your eyes, mouth, nose, genitals hands or the soles of your feet, itching, severe rash, skin pain, skin color changes (redness, yellowing, purplish), swelling and redness of eyes or face, flu-like feeling, joint pain, fatigue, fever, chills, body aches, swollen glands, cough			√
Kidney stones (hard little pebbles that form in your kidneys): blood in		√	

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
urine, urinating more often, pain in your back, side, belly or groin			
Allergic reaction: rash, hives, swelling of the mouth, throat, difficulty swallowing or breathing			√
Liver problems (including liver failure): yellowing of the skin and eyes, dark urine, pale stool, abdominal pain, nausea, vomiting, loss of appetite		√	
Heart problems (including pericarditis and myocarditis or heart inflammation): chest pain, fast or irregular heartbeat, shortness of breath			√
Photosensitivity (sensitivity of the skin to the sun): rash, redness, blisters, itching and burning when the skin is exposed to the sun or UV light	√		
Very rare			
Kidney problems: decreased urination, nausea, vomiting, swelling of extremities, fatigue		√	
Lupus-erythematosus-like syndrome: pain and swelling in the joints, skin rash, fatigue, fever		√	
Lung problems: trouble breathing, wheezing, dry cough, chills, sweating, body aches, fatigue		√	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

PENTASA suppositories should be stored at room temperature, below 25°C. The suppositories should be kept in the original container until ready to use.

Keep out of reach and sight of children.

If you want more information about PENTASA:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database website ([Drug Product Database: Access the database](#)); Ferring Inc's website www.ferring.ca, or by calling 1-866-384-1314.

This leaflet was prepared by



Date of Authorization: 2026-04-16

® Registered Trademark of Ferring BV